These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 7935175)

  • 21. Efficacy of oral irinotecan against neuroblastoma xenografts.
    Thompson J; Zamboni WC; Cheshire PJ; Richmond L; Luo X; Houghton JA; Stewart CF; Houghton PJ
    Anticancer Drugs; 1997 Apr; 8(4):313-22. PubMed ID: 9180383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
    Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
    Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice.
    Kawato Y; Furuta T; Aonuma M; Yasuoka M; Yokokura T; Matsumoto K
    Cancer Chemother Pharmacol; 1991; 28(3):192-8. PubMed ID: 1855276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth inhibition of human gastrointestinal cancer xenograft lines by treatment with CPT-11 and VP-16.
    Nagai S; Yamauchi M; Satta T; Kodera Y; Kondou K; Akiyaya S; Ito K; Takagi H
    J Surg Oncol; 1993 Dec; 54(4):211-5. PubMed ID: 8255079
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts.
    Kaneko S; Kaneko M; Fukushima T
    Int J Clin Oncol; 2013 Feb; 18(1):116-25. PubMed ID: 22127347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
    Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of administration schedules on the antitumor activity of CPT-11, a camptothecin derivative].
    Furuta T; Yokokura T
    Gan To Kagaku Ryoho; 1990 Jan; 17(1):121-30. PubMed ID: 2297233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
    Kim R; Hirabayashi N; Nishiyama M; Jinushi K; Toge T; Okada K
    Int J Cancer; 1992 Mar; 50(5):760-6. PubMed ID: 1312063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
    Koizumi F; Kanzawa F; Ueda Y; Koh Y; Tsukiyama S; Taguchi F; Tamura T; Saijo N; Nishio K
    Int J Cancer; 2004 Jan; 108(3):464-72. PubMed ID: 14648715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
    Miki T; Nonomura N; Takaha N; Nishimura K; Kojima Y; Sawada M; Okuyama A
    Int J Urol; 1998 Jul; 5(4):370-3. PubMed ID: 9712447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
    Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H
    J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
    Matsumoto Y; Fujiwara T; Honjo Y; Sasaoka N; Tsuchida T; Nagao S
    J Surg Oncol; 1993 Jun; 53(2):97-103. PubMed ID: 8388965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl.
    Chen YL; Chueh FS; Yang JS; Hsueh SC; Lu CC; Chiang JH; Lee CS; Lu HF; Chung JG
    Environ Toxicol; 2015 Jul; 30(7):803-15. PubMed ID: 24474168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC; Hooper AT; Bassi R; Ellis LM; Waksal HW; Hicklin DJ
    Clin Cancer Res; 2002 May; 8(5):994-1003. PubMed ID: 12006511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered irinotecan and SN-38 disposition after intravenous and oral administration of irinotecan in mice bearing human neuroblastoma xenografts.
    Zamboni WC; Houghton PJ; Thompson J; Cheshire PJ; Hanna SK; Richmond LB; Lou X; Stewart CF
    Clin Cancer Res; 1998 Feb; 4(2):455-62. PubMed ID: 9516936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts.
    Castellino RC; Elion GB; Keir ST; Houghton PJ; Johnson SP; Bigner DD; Friedman HS
    Cancer Chemother Pharmacol; 2000; 45(4):345-9. PubMed ID: 10755324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [DNA topoisomerase inhibitor as chemotherapeutic drug--clinical point of view].
    Taguchi T
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1574-8. PubMed ID: 1651685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activities and pharmacokinetics of silatecans DB-67 and DB-91.
    Yeh TK; Li CM; Chen CP; Chuu JJ; Huang CL; Wang HS; Shen CC; Lee TY; Chang CY; Chang CM; Chao YS; Lin CT; Chang JY; Chen CT
    Pharmacol Res; 2010 Feb; 61(2):108-15. PubMed ID: 19643180
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
    Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
    Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages.
    Bruns CJ; Shinohara H; Harbison MT; Davis DW; Nelkin G; Killion JJ; McConkey DJ; Dong Z; Fidler IJ
    Cancer Res; 2000 Jan; 60(1):2-7. PubMed ID: 10646841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.